Why the study?
Type 2 diabetes mellitus is a risk factor for ASCVD, making Framingham Risk Score assessment necessary to predict future ASCVD risk.
In patients with type 2 diabetes mellitus on statin therapy, age, gender, total cholesterol, HDL, blood pressure, and smoking remain significant risk factors for 10-year ASCVD risk as predicted by the Framingham Risk Score.
Should not yet change practice; leaves open whether FRS should guide residual-risk intensification in statin-treated T2DM.
Background: Cardiovascular disease is still the number 1 cause of death globally. Meanwhile, type 2 diabetes mellitus (T2DM) is a risk factor for atherosclerosis vascular disease (ASCVD), so an assessment using Framingham Risk Score (FRS) is needed to predict the risk of ASCVD in the future. Objective: Analyzing the risk factor of ASCVD using the Framingham Risk Score (FRS) in T2DM patients. Methods: This study was conducted from July 2020 to July 2021, which the participants were measured for FRS including age, gender, current smoking, diabetes, blood pressure (systolic), high-density lipoprotein (HDL) cholesterol, total cholesterol (TC), and ASCVD risk score. The analysis employed multiple linear tests and ANOVA tests with p < 0.05. Results: Several ASCVD risk factors in T2DM patients were found, including gender (t = 6.015; p < 0.001), age (t = 6.901; p < 0.001), HDL level (t = 2.287; p = 0.024), CT level (t = 5.273; p < 0.001), blood pressure (t = 5.850; p < 0.001), and current smoking (t = 2.638; p = 0.009). The results of analysis between ASCVD risk factor and level of ASCVD risk obtained a significant association (F = 36,642; p < 0.001). Conclusion: Risk factors of ASCVD in T2DM patients such as gender, age, HDL level, CT level, blood pressure, and current smoking. HIGHLIGHTS Risk factors of ASCVD include gender, age, HDL level, CT level, blood pressure, and current smoking in T2DM patients. Significant ASCVD risk factors are age, gender, TC level, and blood pressure. The Framingham Risk Score is used to predict ASCVD in T2DM patients in the next 10 years.
No takes yet. Share an insight, caveat, or question.
Ikhsan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: